NEW YORK (GenomeWeb) – German molecular diagnostics firm Curetis has successfully completed a large clinical trial of its lower respiratory panel (LRP) in anticipation of submitting the panel and its Unyvero system to the US Food and Drug Administration by the end of the year.

The panel is designed for critical lower respiratory tract infections, which are often diagnosed as pneumonia, and detects 21 different pathogens and 19 resistance markers, Curetis' CEO Oliver Schacht told GenomeWeb in an interview. It is currently CE-marked in Europe, where it is known as a pneumonia panel.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.